Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo.

Liu JY, Park SH, Morisseau C, Hwang SH, Hammock BD, Weiss RH.

Mol Cancer Ther. 2009 Aug;8(8):2193-203. doi: 10.1158/1535-7163.MCT-09-0119. Epub 2009 Aug 11.

2.

Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension.

Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD, Imig JD.

Am J Physiol Renal Physiol. 2009 Sep;297(3):F740-8. doi: 10.1152/ajprenal.00098.2009. Epub 2009 Jun 24.

3.
4.

The arachidonic acid epoxygenase is a component of the signaling mechanisms responsible for VEGF-stimulated angiogenesis.

Yang S, Wei S, Pozzi A, Capdevila JH.

Arch Biochem Biophys. 2009 Sep;489(1-2):82-91. doi: 10.1016/j.abb.2009.05.006. Epub 2009 May 21.

5.

Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection.

Simpkins AN, Rudic RD, Schreihofer DA, Roy S, Manhiani M, Tsai HJ, Hammock BD, Imig JD.

Am J Pathol. 2009 Jun;174(6):2086-95. doi: 10.2353/ajpath.2009.080544. Epub 2009 May 12.

6.

Discovery of potent non-urea inhibitors of soluble epoxide hydrolase.

Xie Y, Liu Y, Gong G, Smith DH, Yan F, Rinderspacher A, Feng Y, Zhu Z, Li X, Deng SX, Branden L, Vidović D, Chung C, Schürer S, Morisseau C, Hammock BD, Landry DW.

Bioorg Med Chem Lett. 2009 Apr 15;19(8):2354-9. doi: 10.1016/j.bmcl.2008.09.066. Epub 2008 Sep 20.

7.

Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo.

Chen C, Li G, Liao W, Wu J, Liu L, Ma D, Zhou J, Elbekai RH, Edin ML, Zeldin DC, Wang DW.

J Pharmacol Exp Ther. 2009 Jun;329(3):908-18. doi: 10.1124/jpet.109.152017. Epub 2009 Mar 16.

8.

Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells.

Katragadda D, Batchu SN, Cho WJ, Chaudhary KR, Falck JR, Seubert JM.

J Mol Cell Cardiol. 2009 Jun;46(6):867-75. doi: 10.1016/j.yjmcc.2009.02.028. Epub 2009 Mar 12.

PMID:
19285984
9.

Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats.

Revermann M, Barbosa-Sicard E, Dony E, Schermuly RT, Morisseau C, Geisslinger G, Fleming I, Hammock BD, Brandes RP.

J Hypertens. 2009 Feb;27(2):322-31.

10.

Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy.

Ai D, Pang W, Li N, Xu M, Jones PD, Yang J, Zhang Y, Chiamvimonvat N, Shyy JY, Hammock BD, Zhu Y.

Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):564-9. doi: 10.1073/pnas.0811022106. Epub 2009 Jan 6.

11.

Effect of 20-HETE inhibition on infarct volume and cerebral blood flow after transient middle cerebral artery occlusion.

Renic M, Klaus JA, Omura T, Kawashima N, Onishi M, Miyata N, Koehler RC, Harder DR, Roman RJ.

J Cereb Blood Flow Metab. 2009 Mar;29(3):629-39. doi: 10.1038/jcbfm.2008.156. Epub 2008 Dec 24.

12.

Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways.

Inceoglu B, Jinks SL, Ulu A, Hegedus CM, Georgi K, Schmelzer KR, Wagner K, Jones PD, Morisseau C, Hammock BD.

Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18901-6. doi: 10.1073/pnas.0809765105. Epub 2008 Nov 21.

13.

Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase.

EnayetAllah AE, Luria A, Luo B, Tsai HJ, Sura P, Hammock BD, Grant DF.

J Biol Chem. 2008 Dec 26;283(52):36592-8. doi: 10.1074/jbc.M806315200. Epub 2008 Oct 29.

14.

Arachidonic acid cytochrome P450 epoxygenase pathway.

Spector AA.

J Lipid Res. 2009 Apr;50 Suppl:S52-6. doi: 10.1194/jlr.R800038-JLR200. Epub 2008 Oct 23. Review.

15.

Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo.

Motoki A, Merkel MJ, Packwood WH, Cao Z, Liu L, Iliff J, Alkayed NJ, Van Winkle DM.

Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H2128-34. doi: 10.1152/ajpheart.00428.2008. Epub 2008 Oct 3.

16.

Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation.

Fife KL, Liu Y, Schmelzer KR, Tsai HJ, Kim IH, Morisseau C, Hammock BD, Kroetz DL.

J Pharmacol Exp Ther. 2008 Dec;327(3):707-15. doi: 10.1124/jpet.108.142398. Epub 2008 Sep 24.

17.

Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model.

Ulu A, Davis BB, Tsai HJ, Kim IH, Morisseau C, Inceoglu B, Fiehn O, Hammock BD, Weiss RH.

J Cardiovasc Pharmacol. 2008 Oct;52(4):314-23. doi: 10.1097/FJC.0b013e318185fa3c.

18.

Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response.

Keserü B, Barbosa-Sicard E, Popp R, Fisslthaler B, Dietrich A, Gudermann T, Hammock BD, Falck JR, Weissmann N, Busse R, Fleming I.

FASEB J. 2008 Dec;22(12):4306-15. doi: 10.1096/fj.08-112821. Epub 2008 Aug 25.

19.

Current pharmacological treatment of pulmonary arterial hypertension.

Steiropoulos P, Trakada G, Bouros D.

Curr Clin Pharmacol. 2008 Jan;3(1):11-9. Review.

PMID:
18690874
20.

Soluble epoxide hydrolase homologs in Strongylocentrotus purpuratus suggest a gene duplication event and subsequent divergence.

Harris TR, Aronov PA, Hammock BD.

DNA Cell Biol. 2008 Sep;27(9):467-77. doi: 10.1089/dna.2008.0751.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk